Bioinformatics Analysis Reveals That CBX2 Promotes Enzalutamide Resistance in Prostate Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Aug 22

PMID 39175037

Authors

Zhu Wen

Qinghua Li

Guangmo Hu

Affiliations

Soon will be listed here.

Abstract

Enzalutamide (Enz) is commonly utilized as the initial treatment strategy for advanced prostate cancer (PCa). However, a notable subset of patients may experience resistance to Enz, resulting in reduced effectiveness. Utilizing Gene Expression Omnibus (GEO) databases, we identified CBX2 as a crucial factor in mediating resistance to Enz, primarily due to its inhibitory effect on the P53 signaling pathway. Silencing of CBX2 using small interfering RNA (siRNA) led to elevated levels of P53 expression in LNCaP cells. This indicates that CBX2 may have a critical effect on PCa Enz resistance and could serve as a promising therapeutic target for individuals with Enz resistance.

References

Di Lorenzo G, Buonerba L, Ingenito C, Crocetto F, Buonerba C, Libroia A . Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. Oncology. 2020; 98(10):743-747. PMC: 7360489. DOI: 10.1159/000509434. View

Xu X, Lai C, Luo J, Shi J, Guo K, Hu J . The predictive significance of chromobox family members in prostate cancer in humans. Cell Oncol (Dordr). 2024; 47(4):1315-1331. DOI: 10.1007/s13402-024-00929-7. View

Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F . PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012; 45(3):344-56. PMC: 3293217. DOI: 10.1016/j.molcel.2012.01.002. View

Zhang H, Luo Y, Wu W, Zhang L, Wang Z, Dai Z . The molecular feature of macrophages in tumor immune microenvironment of glioma patients. Comput Struct Biotechnol J. 2021; 19:4603-4618. PMC: 8383063. DOI: 10.1016/j.csbj.2021.08.019. View

Li S, Fong K, Gritsina G, Zhang A, Zhao J, Kim J . Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019; 79(10):2580-2592. PMC: 6522281. DOI: 10.1158/0008-5472.CAN-18-2812. View

Song D, Jia X, Liu X, Hu L, Lin K, Xiao T . Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct Target Ther. 2022; 7(1):100. PMC: 8989880. DOI: 10.1038/s41392-022-00921-3. View

Wang W, Li X, Guan C, Hu Z, Zhao Y, Li W . LncRNA PCAT6 promotes the proliferation, migration and invasion of pancreatic ductal adenocarcinoma via regulating miR-185-5p/CBX2 axis. Pathol Res Pract. 2020; 216(9):153074. DOI: 10.1016/j.prp.2020.153074. View

Park S, Fong K, Mong E, Martin M, Schiltz G, Yu J . Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene. 2021; 40(39):5788-5798. PMC: 8487936. DOI: 10.1038/s41388-021-01982-4. View

Su W, Han H, Wang Y, Zhang B, Zhou B, Cheng Y . The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell. 2019; 36(2):139-155.e10. PMC: 7210785. DOI: 10.1016/j.ccell.2019.06.009. View

10.

Chen H, Shi B, Wu Y, Qian Y, Zhou J, Zhang X . The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone. Int Urol Nephrol. 2022; 54(4):749-756. DOI: 10.1007/s11255-022-03113-8. View

11.

Ge R, Wang Z, Montironi R, Jiang Z, Cheng M, Santoni M . Epigenetic modulations and lineage plasticity in advanced prostate cancer. Ann Oncol. 2020; 31(4):470-479. DOI: 10.1016/j.annonc.2020.02.002. View

12.

Guerrero J, Alfaro I, Gomez F, Protter A, Bernales S . Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013; 73(12):1291-305. DOI: 10.1002/pros.22674. View

13.

Del Gaudio N, Di Costanzo A, Liu N, Conte L, DellAversana C, Bove G . CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Mol Cancer. 2022; 21(1):125. PMC: 9178829. DOI: 10.1186/s12943-022-01603-y. View

14.

Luo Z, Wang W, Li F, Songyang Z, Feng X, Xin C . Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes. Mol Cancer. 2019; 18(1):106. PMC: 6556968. DOI: 10.1186/s12943-019-1035-x. View

15.

Clermont P, Crea F, Chiang Y, Lin D, Zhang A, Wang J . Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016; 8:16. PMC: 4751702. DOI: 10.1186/s13148-016-0182-9. View

16.

Han J, Zhou Y, Zhang C, Feng J, Wang J, Guo K . Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes. J Cell Mol Med. 2022; 27(1):101-112. PMC: 9806298. DOI: 10.1111/jcmm.17641. View

17.

Rezaei Z, Ranjbaran J, Safarpour H, Nomiri S, Salmani F, Chamani E . Identification of early diagnostic biomarkers via WGCNA in gastric cancer. Biomed Pharmacother. 2021; 145:112477. DOI: 10.1016/j.biopha.2021.112477. View

18.

Wang S, Alpsoy A, Sood S, Ordonez-Rubiano S, Dhiman A, Sun Y . A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation. Chembiochem. 2021; 22(13):2335-2344. PMC: 8358665. DOI: 10.1002/cbic.202100118. View

19.

Liu Y, Yao Y, Zhang Y, Xu C, Yang T, Qu M . Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma. BMC Med Genomics. 2024; 17(1):121. PMC: 11067181. DOI: 10.1186/s12920-024-01870-2. View

20.

Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K . Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022; 81(5):446-455. PMC: 9018600. DOI: 10.1016/j.eururo.2021.12.039. View